• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Reyataz (atazanavir sulfate)

Audience: Infectious Disease and other healthcare professionals

BMS and FDA notified clinicians caring for HIV-infected patients of important new safety data concerning the coadministration of Reyataz (atazanavir sulfate) and Viread (tenofovir disoproxil fumarate.) Clinicians should use caution when administering unboosted Reyataz with tenofovir DF. Unboosted Reyataz may be less effective due to decreased atazanavir concentrations in patients taking Reyataz and tenofovir DF. As a result the coadministration of unboosted Reyataz with tenofovir DF may lead to loss or lack of virologic response and possible resistance to Reyataz.

[August 8, 2003 - Letter - BMS]